欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (12): 1376-1380.doi: 10.12092/j.issn.1009-2501.2020.12.009

• 临床药理学 • 上一篇    下一篇

pazopanib血药浓度个体差异与细胞色素P450 3A4基因多态性的关系初探

吴茂锋1,刘畅1,戴慧晖1,麦长凤1,黄丹丽1,缪经纬1,刘丽忠1,方翼1,2
  

  1. 1广州医科大学 附属第六医院/清远市人民医院 药物Ⅰ期临床研究室,清远 511518,广东;2北京大学人民医院 药剂科,北京 100044
  • 收稿日期:2020-07-16 修回日期:2020-08-13 出版日期:2020-12-26 发布日期:2021-01-04
  • 通讯作者: 刘丽忠,女,博士,主任医师,研究方向:新药临床评价。 Tel: 19807630328 E-mail: lindallz@163.com
  • 作者简介:吴茂锋,男,硕士研究生,主管技师,研究方向:药物基因组学检测。 Tel: 15626206660 E-mail: wmf695@163.com
  • 基金资助:
    清远市科技计划基金资助项目(DZXQY002);清远市人民医院医学科研基金资助项目(20190208)

Preliminary association of individual different plasma pazopanib concentration with CYP3A4 gene polymorphism

WU Maofeng 1, LIU Chang 1, DAI Huihui 1, MAI Zhangfeng 1, HUANG Danli 1, MIAO Jingwei 1, LIU Lizhong 1, FANG Yi 1,2   

  1. 1 Phase I Clinical Research Unit, the Sixth Affiliated Hospital of Guangzhou Medical University/Qingyuan People's Hospital, Qingyuan 511518, Guangdong, China; 2 Department of Pharmacy, Peking University People's Hospital, Beijing 100044, China
  • Received:2020-07-16 Revised:2020-08-13 Online:2020-12-26 Published:2021-01-04

摘要: 目的:分析健康受试者口服pazopanib片后体内药代动力学(PK)规律,初步探讨pazopanib片PK个体差异的遗传学机制。方法:14例健康男性受试者分别在给药当天单次口服pazopanib片(200 mg)后,采集基线至96 h血液样本,用LC-MS/MS法测定服药后各时间点血药浓度,用WinNonlin 6.3软件计算药代动力学相关参数,采用SNapShot法测定细胞色素P450 3A4(CYP3A4)基因多态性。结果:Cmax变化范围(7 361.65-26 081.00) ng/mL,平均值±标准差(15 410.72±6 366.21) ng/mL ;tmax变化范围(1.50-4.00) h、平均值±标准差(2.50±0.83) h;AUC0-t变化范围(228 013.55-775 231.63)ng·mL-1·h,平均值±标准差(516 279.90±175 688.41)ng·mL-1·h。个体间Cmax、AUC相差达3倍以上,tmax可相差2倍以上;14例受试者CYP3A4(RS35599367)位点皆为野生型。结论:pazopanib片在中国健康男性志愿者中个体差异较大,未观察到CYP3A4(rs35599367)位点单核苷酸多态性,pazopanib个体间PK差异可能与其他药物代谢相关基因多态性有关。

关键词: pazopanib, 细胞色素P450 3A4, 基因多态性

Abstract: AIM: To study the pharmacokinetics (PK) of pazopanib tablets and explore the genetic mechanism of individual differences in drug metabolism primarily.  METHODS: Fourteen healthy male subjects were respectively administrated with a single dose pazopanib tablet (200 mg) orally on the day of dosing, and their blood samples were collected from baseline to 96 hours. The serum concentration of pazopanib was measured by LC-MS/MS, the parameters of PK were calculated by winnonlin 6.3 software, and the gene polymorphism of cytochrome P450 3A4 (CYP3A4) was determined by snapshot method. RESULTS: The range of Cmax was (7 361.65-26 081.00) ng/mL, with an average±sd of (15 410.72±6 366.21) ng/mL; the range of tmax was (1.50-4.00) h, with an average±sd of (2.50±0.83) h; AUC0-t range was (228 013.55-775 231.63) ng·mL-1·h, average±sd was (516 279.90±175 688.41) ng·mL-1·h; tmax could differ by more than 2 times between individuals, and Cmax and AUC could differ by more than 3 times. CYP3A4 site (rs35599367) of 14 subjects were all wild-type. CONCLUSION: The pazopanib tablets have large individual differences among Chinese healthy male volunteers, but no CYP3A4 (rs35599367) polymorphism differences were observed in this study. Individual PK differences of pazopanib may be related to polymorphisms of other drug metabolism related genes.

Key words: pazopanib, cytochrome P450 3A4, gene polymorphism

中图分类号: